“The term ‘cardiogenic dementia’ was coined based mainly on studies that documented lower left ventricular ejection fraction (LVEF) in patients suffering from cardiovascular diseases and dementia. However, some studies provide data that LVEF is not a marker of dementia in some groups of patients,” said Dr Karol Nowak (Jagiellonian University Medical College, Poland) [1]. Thus, Dr Nowak and colleagues performed detailed ECG assessments in patients following decompensated heart failure with and without SDD.
Included were 139 patients aged ≥65 years who were hospitalised for decompensated heart failure, and enrolled between 2008 and 2017. During their in-patient stay, clinical and laboratory, as well as detailed ECG measures were obtained. After their release, the patients were followed up with extensive questionnaires including the Adult Lifestyles and Function Interview-Mini-Mental State Examination (ALFI-MMSE) to evaluate for an SDD. Based on the presence of an ALFI-MMSE score <17 points that stood for SDD, 2 subgroups were investigated.
“The baseline characteristics of our study revealed older age, higher prevalence of renal failure, higher level of creatinine, lower glomerular filtration rate, lower haemoglobin, and lower haematocrit in patients with SDD,” said Dr Nowak. Within the ECG measures, there were significant inter-group differences for interventricular septal diastolic diameter (P=0.021), aortic valve peak gradient (P=0.013), posterior wall diastolic diameter (P=0.005), and relative wall thickness (P=0.004), all with higher values in the SDD group.
Using a multivariate model, the study also assessed independent predictors of patients’ ALFI-MMSE scores. The results revealed an independent correlation between older age as well as relative wall thickness and SDD. “The predictive value of relative wall thickness was the highest among all ECG parameters,” underlined Dr Nowak. The authors concluded that this is the first research providing ECG data in this unique SDD group of patients following heart failure decompensation.
- Nowak K, et al. Acute exacerbation of chronic congestive heart failure and cognitive impairment coexistency in elderly patients-the first echocardiographic measurements. P60749, Heart Failure and World Congress on Acute Heart Failure 2021, 29 June–1 July.
Copyright ©2021 Medicom Medical Publishers
Posted on
Previous Article
« Telemedicine: Every light has its shadow Next Article
Weight loss associated with increased mortality risk in heart failure patients »
« Telemedicine: Every light has its shadow Next Article
Weight loss associated with increased mortality risk in heart failure patients »
Table of Contents: HFA 2021
Featured articles
Inconclusive results for dapagliflozin treatment in heart failure
Late-Breaking Trials
Iron substitution improves LVEF in intensively treated CRT patients with iron deficiency
Novel mineralocorticoid receptor antagonist effective irrespective of HF history
Iron substitution in iron-deficient HF patients is highly cost-effective
Omecamtiv mecarbil might be less effective in patients with atrial fibrillation or flutter
Vericiguat effective irrespective of atrial fibrillation status
Baroreflex activation: a novel option to improve heart failure symptoms
Beta-blocker withdrawal to enhance exercise capacity in heart failure?
Inconclusive results for dapagliflozin treatment in heart failure
Computerised cognitive training improves cognitive function in HF patients
COVID-19 and the Heart
COVID-19-related HF: from systemic infection to cardiac inflammation
Myocardial infarction outcomes were significantly affected by the pandemic
TAPSE effective biomarker associated with high-risk of severe COVID-19
COVID-19 in AF patients with HF: no higher mortality but longer hospital stay
Cancer and the Heart
Heart failure patients might be at an increased risk for head and neck cancer
Trastuzumab associated with cardiotoxicity in breast cancer
Heart Failure Prevention and HRQoL in the 21st century
Psychoactive substances put young people at risk of cardiovascular disease
The challenge of improving the quality of life of heart failure patients
SGLT2 Inhibitors in Heart Failure
Empagliflozin linked to lower cardiovascular risk and renal events in real-world study
Efficacy of dapagliflozin and empagliflozin not influenced by diabetes status
Biomarker panel predicts SGLT2 inhibitor response
Best of the Posters
Real-world study suggests sacubitril/valsartan benefits elderly patients with HF
Proenkephalin: A useful biomarker for new-onset heart failure?
Weight loss associated with increased mortality risk in heart failure patients
Echocardiographic parameters linked to dementia diagnosis
Related Articles
September 2, 2024
FINEARTS-HF: Finerenone helps across ejection fraction spectrum
September 7, 2020
Sacubitril-valsartan in hospitalized HF patients could have benefits
© 2024 Medicom Medical Publishers. All rights reserved. Terms and Conditions | Privacy Policy
HEAD OFFICE
Laarderhoogtweg 25
1101 EB Amsterdam
The Netherlands
T: +31 85 4012 560
E: publishers@medicom-publishers.com